BioSET about us banner

Our Story

History
Biosurface Engineering Technologies™ [BioSET®] was formed in 2001 with over 10 years of research and development in surface modification and drug coating of medical implants. Spun out of U.S. Surgical’s acquisition of InnerDyne, Inc. in 2000, BioSET established operations in the biotech corridor of Rockville, Maryland, after co-developing a novel peptide technology platform in collaboration with Brookhaven National Laboratory of New York. This discovery has led to the development of a suite of bioactive peptides that mimic select biologic aspects of native human growth factors, such as BMP’s, FGF’s and PDGF’s. These biomimetic peptides have shown promise in improving the body’s healing response in various applications of tissue repair in a range of pre-clinical studies. Based on these encouraging results, BioSET has advanced their lead compound, B2A®, a peptide modeled on bone morphogenic protein 2 (BMP2), into human clinical trials for the treatment of debilitating degenerative spinal disease.

Focus
Using BioSET’s suite of biomimetic growth factor peptides, the company’s goal is to pair the most appropriate signaling molecule with tissue-specific scaffolds for advanced tissue regeneration in bone and soft tissue repair.

BioSET’s lead product is AMPLEX™, a combination of the B2A peptide and a synthetic ceramic scaffold with chemical properties similar to that of native bone. AMPLEX is currently under investigation in human clinical trials as a surgical bone graft implant for lumbar degenerative disc disease, a painful and debilitating condition of the spine.

BioSET’s products have the opportunity to realize the tremendous advantages of combination products and revolutionize the role of surgical implants used in musculoskeletal surgery.

Strategy
At BioSET, our strategy is to address medical conditions of high clinical need in an area where surgeons and providers recognize the benefit that osteobiologics bring to improving outcomes and reducing the overall cost of healthcare delivery. Adoption of our advanced osteobiologics in spine surgery will, in turn, further enable commercialization of our technology in additional applications within musculoskeletal surgery.